A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Phase 2 Induction Study With Long-Term Extension to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants w/ Moderate to Severe Ulcerative Colitis

Protocol No

GI-LANDOS-NX-13-201

Staff Member

Poonam Beniwal-Patel

Phase

Summary

This project is being done to find out more about NX-13, an investigational drug, in people with ulcerative colitis. We want to determine if it reduces the symptoms of ulcerative colitis, and whether it causes any problems (side effects).

Objective

Oral NX-13 in Moderate to Severe Ulcerative Colitis

Study Sites

Froedtert Hospital

Status

OPEN TO ACCRUAL